RxDoctor Payments Data

Braedon Collins, MD

Urology · Springdale, ARNPI 1356725055

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $7,728 of the $9,669 with a category attached, or 79.9%. 45 manufacturers reported payments, led by Boston Scientific at 35.9% of the total.

$9,669in general payments, 2019–2025

Across 213 payments — averaging $45.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$3K
  • Axonics, Inc.$2K
  • Medtronic$1K
  • Procept Biorobotics Corporation$643
  • Teleflex LLC$339
  • Agiliti Health, Inc.$270
  • plus $2K from 39 others

What the payments were for

  • Travel & lodging$1,85219%
  • Food & beverage$7,72880%
  • Education$901%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,669 in reported general payments places this provider in the 65th percentile of 88 urology providers in Arkansas.

See all urology providers in Arkansas

Medicare billing

Part B allowed, 2024
$116,349
Medicare patients
319
Services billed
1,719

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron113$73,212
GemtesaVibegron67$47,799
Tamsulosin Hcl587$6,777
Trospium Chloride40$2,310
Estradiol29$1,870
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst29$1,095
Testosterone Cypionate30$815
Solifenacin Succinate35$707
Methenamine Hippurate14$687
Oxybutynin Chloride ErOxybutynin Chloride33$463
Alfuzosin Hcl ErAlfuzosin Hcl39$457
Cephalexin37$243
Finasteride35$234
Sildenafil Citrate12$230
Cefdinir36$177

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$140$73,212113 claims
Sumitomo Pharma America, Inc.Gemtesa$218$47,79967 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 88 urology providers in Arkansas.

Other urology in Springdale

See the full list for Arkansas

Where these figures come from

Is this you, or does something look wrong? →